Vanguard Group Inc Taysha Gene Therapies, Inc. Call Options Transaction History
Vanguard Group Inc
- $5.57 Trillion
- Q4 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding TSHA
# of Institutions
127Shares Held
143MCall Options Held
56.6KPut Options Held
13.3K-
Avoro Capital Advisors LLC New York, NY20MShares$35 Million0.5% of portfolio
-
Morgan Stanley New York, NY17.6MShares$30.9 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.7MShares$20.5 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA10.9MShares$19 Million0.3% of portfolio
-
Octagon Capital Advisors LP New York, NY10.5MShares$18.3 Million4.03% of portfolio
About Taysha Gene Therapies, Inc.
- Ticker TSHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,359,500
- Market Cap $84.6M
- Description
- Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...